# Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

> **NCT02034110** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 206 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Dabrafenib
- **DRUG:** Trametinib

## Key facts

- **NCT ID:** NCT02034110
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-12
- **Primary completion:** 2021-12-10
- **Final completion:** 2021-12-10
- **Target enrollment:** 206 (ACTUAL)
- **Last updated:** 2023-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02034110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02034110, "Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02034110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*